Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) Non Operating Income: 2020-2025

Historic Non Operating Income for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to $14.1 million.

  • Beam Therapeutics' Non Operating Income rose 43.18% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.6 million, marking a year-over-year increase of 27.55%. This contributed to the annual value of $38.9 million for FY2024, which is 14.25% down from last year.
  • Beam Therapeutics' Non Operating Income amounted to $14.1 million in Q3 2025, which was down 21.15% from $17.9 million recorded in Q2 2025.
  • Beam Therapeutics' 5-year Non Operating Income high stood at $51.6 million for Q4 2022, and its period low was -$17.3 million during Q2 2021.
  • Over the past 3 years, Beam Therapeutics' median Non Operating Income value was $11.3 million (recorded in 2023), while the average stood at $11.5 million.
  • In the last 5 years, Beam Therapeutics' Non Operating Income tumbled by 721.64% in 2021 and then skyrocketed by 4,322.08% in 2022.
  • Over the past 5 years, Beam Therapeutics' Non Operating Income (Quarterly) stood at -$1.2 million in 2021, then surged by 4,322.08% to $51.6 million in 2022, then slumped by 78.11% to $11.3 million in 2023, then fell by 14.35% to $9.7 million in 2024, then soared by 43.18% to $14.1 million in 2025.
  • Its last three reported values are $14.1 million in Q3 2025, $17.9 million for Q2 2025, and $10.0 million during Q1 2025.